Sentences with phrase «tumor progression by»

Soluble Antibodies Promote Tumor Progression by Inducing Immune Suppressive Cells Genetic Engineering & Biotechnology News April 13, 2018

Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid - like stromal network.

«The finding that certain cell signaling lipids change the activity of an oncogenic Ras protein, suggests that we might be able to interfere with tumor progression by inhibiting the enzymes which make the specific cell signaling lipid in cells,» Buck said.

Using human - derived glioblastoma cells in a mouse models, researchers found that the modified high - fat, low - carbohydrate diet increased life expectancy by 50 percent while also reducing tumor progression by a similar amount.

Not exact matches

The diagnosis of cancer and study of disease progression is often accomplished by examining a tumor sample containing many billions or even trillions of cells.

The research shows that ONA reduces the progression of malignant ovarian cancer tumors by interfering with the pro-tumor function of myeloid cells.

In demonstrating that FOXO4 works to prevent the spread of cancerous tumors by binding to and inhibiting the protein RUNX2, the team identified a circuit that controls metastatic progression in prostate cancer.

The theory that cancer progression involves the acquisition by tumor cells of features similar to those of stem cells has gained strength in the scientific community.

Researchers found that genetically disrupting this pathway, or using the FDA - approved Src kinase inhibitor dasatinib, increases PUMA levels and decreases tumor progression and metastasis in mice by up to fivefold.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

One adaptation to this fortunate reality is that rather than using overall survival (OS) as the measure of a drug's success, many clinical trials now use a kind of midpoint, namely progression - free survival (PFS)-- the time that it takes for a tumor controlled by the trial's medicine to restart its growth.

NK cells require active STAT5 to kill tumor cells; however, when STAT5 is absent or inhibited, NK cells do the opposite: they accelerate cancer progression by promoting angiogenesis.

The trial included three groups of patients: those who did not undergo surgery following infusion (three patients who had multi-focal and recurrent tumors not amenable to surgical resection prior to infusion); those who underwent «late surgery» (three patients who had surgery once at either day 34, day 55, or day 104 following infusion); and those who underwent «early surgery» (four patients who had clear symptomatic progression leading to a combined regimen of CART infusion followed by clinically indicated surgery).

Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented Oct. 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego.

«Eliminating endothelial CD146 by conditional knockout in two different mouse models of colitis significantly reduced the severity of inflammation and decreased tumor incidence and tumor progression in a mouse model of CAC,» reports lead investigator Xiyun Yan, PhD, from the Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing.

She also noted the targeting Msi in primary tumors significantly changed «the trajectory of progression by halting pancreatic cancer growth and improving survival,» inhibiting both cancer stem cells and other tumor cells.

Unlike previous studies, which tracked lymphoma progression by monitoring the sequence of just one cancer - associated protein, CAPP - Seq can identify a much larger range of mutations in the tumor genome.

«For example, restoring the lost enzymes in the two metabolic pathways might slow tumor progression and reduce aggressiveness by inactivating oncogenic kinases and activating immune responses,» says Chakravarti, who holds the Max Morehouse Chair in Cancer Research.

An extension of this model, however, proposes that EMT forms a key mechanistic basis for the progression of malignant tumors (reviewed by Nieto MA [1]-RRB-.

Nefedova studies molecular mechanisms by which bone marrow microenvironment promotes tumor survival and progression.

Collectively, our results indicated that RASSF1 acts to restrict EMT and invasion by indirectly controlling YAP nuclear shuttling and activation through a RhoB - regulated cytoskeletal remodeling process, with potential implications to delay the progression of RASSF1 - hypermethylated lung tumors.

Inactivation of the tumor suppressor gene RASSF1A by promoter hypermethylation represents a key event underlying the initiation and progression of lung cancer.

Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.

$ 1.8 M Supports Cancer Drug Discovery on Commonly Mutated Gene New Brunswick Patch — April 5, 2016 Behavioral Scientist Shares Insights about FDA's Proposed Rule on Banning Tanning Bed Use among Minors News-Medical.net - March 19, 2016 Intervention Program Reduces Caregiver Distress during Hospitalization of Pediatric Stem Cell Transplant Patients News-Medical.net - March 9, 2016 Exploring Genomic Pathways in the Development of Ovarian Cancer GMNews.com - March 2, 2016 Differences in Type of Small Protein may further Elucidate Lung Cancer Risk in African Americans ScienceDaily.com - March 2, 2016 Study Looks at Post-Treatment Resources for Prostate Cancer Patients Transitioning to Survivorship News-Medical.net - February 11, 2016 Drawing the Line on Tanning Bed Use by Teens ScienceDaily.com - December 21, 2015 What Rutgers Study Uncovered about E-Cigarette Use NJBiz.com - December 9, 2015 Identification of Barrier that Prevents Progression of Benign Kidney Tumors to Malignant Disease MedicalNewsToday.com - November, 24, 2015 What is the Color of the Lung Cancer Ribbon?

Anna Huttenlocher, University of Wisconsin, USA Neutrophils in the Tumor Microenvironment Neutrophils, Wounds, and Cancer Progression Stefan Kaufmann, Max Planck Institute, Germany Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells Kathryn Moore, New York University, USA MicroRNA -33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis Lalita Ramakrishnan, University of Cambridge, UK Myeloid Growth Factors Promote Resistance to Mycobacterial Infection by Curtailing Granuloma Necrosis through Macrophage Replenishment Beth Stevens, Harvard University, USA Microglia: Dynamic Mediators of Synapse Development and Plasticity Do glia drive synaptic and cognitive impairment in disease?

11/13/2008 How Eating Red Meat Can Spur Cancer Progression Researchers at the University of California, San Diego School of Medicine, led by Ajit Varki, M.D., have shown a new mechanism for how human consumption of red meat and milk products could contribute to the increased risk of cancerous tumors.

Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.

During tumor development, rapid expansion of cancer cells creates a hypoxic microenvironment that is followed by periods of reoxygenation to promote tumor progression.

Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time.

Our hypothesis is that tumor progression can be aborted by blocking the aberrant transcription mediated by beta - catenin.

Cell migration is a key step shared by both angiogenesis and tumor progression.

They found that innate immune responses in the tumor microenvironment mimic those stimulated by infection and likely contribute to tumor progression.

TGFβ inhibits tumor initiation and progression by inducing cell cycle arrest and apoptosis; however epithelial tumorigenesis may escape this common antitumor mechanism by inducing aberrations in TGFβ signaling resulting in enhanced development and progression of human carcinomas.

the role of the microenvironment created by inflammation and the inflammatory signaling molecules in the formation and progression of tumors

The idea was to identify genes that were metastasis determinants by correlating gene expression with some kind of invasion assay that measured tumor progression.

We aim to illuminate mechanisms by which Sema3C contributes to tumor progression.

The hypothesis was that the metastatic progression of the prostate cancer could be halted by reducing the tumor cells lipid production and the results were encouraging.

Preliminary evidence from the small clinical trial, led by William Gillanders, MD, also suggests that the vaccine primed the patients» immune systems to attack tumor cells and helped slow the cancer's progression.

The mission of our lab is to improve therapy for patients with brain tumors by elucidating the molecular mechanisms driving cancer initiation and progression, and in doing so, promote rigorous science and train the next generation of scientists.

Local tumor recurrence or tumor progression can be delayed by months to years with CFRT, and a local cure may be obtained in many instances.

By noting patterns of cancer development, doctors and veterinarians may become aware of environmental factors that could be causing tumor progression in different species, including humans.»